Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;269(3):1688-1690.
doi: 10.1007/s00415-021-10811-3. Epub 2021 Sep 22.

Natalizumab-induced pneumonitis

Stefania Kaninia  1   2 , Anthony J Edey  3 , Nick A Maskell  2   4 , Claire M Rice  5   6
Affiliations

Natalizumab-induced pneumonitis

Stefania Kaninia et al. J Neurol. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no disclosures relevant to the manuscript.

Figures

Fig. 1
Fig. 1
Peripheral blood eosinophil count. Baseline eosinophil counts were normal but increased after introduction of Natalizumab. Following presentation with pneumonitis at 6 months, Natalizumab was withdrawn, and eosinophilia resolved
Fig. 2
Fig. 2
CT chest imaging. CT of the thorax at presentation (A) demonstrated extensive broncho-centric and peripheral ground glass opacification with superimposed interlobular septal thickening. Changes had resolved 2 months following discontinuation of Natalizumab (B)
See this image and copyright information in PMC

References

    1. Diem L, Hoepner R, Bagnoud M, et al. Natalizumab induced blood eosinophilia: a retrospective pharmacovigilance cohort study and review of the literature. J Neuroimmunol. 2021;353:577505. doi: 10.1016/j.jneuroim.2021.577505. - DOI - PubMed
    1. Yasuda Y, Nagano T, Tachihara M, et al. Eosinophilic pneumonia associated with natalizumab in a patient with multiple sclerosis: a case report and literature review. Ther Clin Risk Manage. 2019;15:1283–1289. doi: 10.2147/TCRM.S225832. - DOI - PMC - PubMed
    1. Curto E, Munteis-Olivas E, Balcells E, Domínguez-Álvarez MM. Pulmonary eosinophilia associated to treatment with natalizumab. Ann Thorac Med. 2016;11:224–226. doi: 10.4103/1817-1737.185762. - DOI - PMC - PubMed
    1. Andre M, Pacheco D, Antunes J, et al. Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis. Derm Online J. 2010;16:14. - PubMed
    1. Bujold J, Boivin C, Amin M, et al. Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis. J Cutan Med Surg. 2014;18:69–71. doi: 10.2310/7750.2013.13026. - DOI - PubMed

MeSH terms